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Abstract. One of the many challenges in the field of medicine is to
make the best decisions about optimal treatment plans for patients. Med-
ical practitioners often have differing opinions about the best treatment
among multiple available options. While standard protocols are in place
for the first and second lines of treatment for most diseases, a lot of varia-
tion exists in the treatment plans subsequently chosen. We propose to ex-
tensively study recommended treatment guidelines and plans for selected
rare and chronic diseases. As representative diseases we study Glioblas-
toma Multiforme (brain cancer) which is classified as a rare disease, and
Diabetes Mellitus, which is a nationally and globally widespread chronic
disease. A graph model is designed to capture the data pertaining to the
treatment options and historical evidence and further analyzed to dis-
cover sequential treatment patterns based on different outcome classes
based on longevity, complications etc. The notion of ‘Patient Similar-
ity’ would be explored to form cohorts of clinically similar patients. The
treatment patterns would be ranked, and highly ranked patterns would
be ordered depending on expected outcomes before being assigned to co-
horts of patients. A prototype decision support system is planned for
recommending treatment options based on a patients clinical profile.
Evaluation of the models involves using historical data with various eval-
uation metrics and also by a qualitative assessment by expert physicians.
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1 Introduction
Evidence-based medicine refers to the explicit and exhaustive use of available
medical evidence to improve quality of care provided. It involves integration of
individual clinical expertise with the best available external clinical evidence
from systematic research [17]. When deciding on the treatments for patients,
medical practitioners consult both clinical evidence and use their own clinical
expertise and experience to inform their decisions and recommendations to pa-
tients. Variability in such recommendations among multiple practitioners could
directly affect a patient’s wellbeing and recovery. A key challenge in the field
of medicine, faced by a physician, is determining the optimal treatment for a
given patient. While protocols exist for first and second line treatments for the
vast majority of diseases, tailoring treatments to an individual patient presents
a huge diagnostic challenge. With the ever-expanding treatment options, there
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is an increasing need for a system to identify treatment patterns and new drugs
that would cure the patient in the most efficient manner. Treatment is also a
dynamic process, and must evolve as new information becomes available such as
response to a particular treatment approach which may be positive or adverse
during the course of treatment.
In acute conditions, the goal is to find a “cure” or treatment to reverse or
at least arrest the progression of disease typically manifested in a variety of ag-
gressive cancers. On the other hand, in chronic diseases like diabetes or renal
disease, the goal is to manage the disease state and prevent further deterioration
or progression to more serious conditions. Part of chronic disease management
is to identify and prescribe measures for improving the quality of life. Toward
this end, we have selected two specific diseases for analysis, namely Glioblastoma
Multiforme (GBM), and Diabetes Mellitus. GBM is the most lethal type of brain
cancer and is biologically the most aggressive subtype of malignant gliomas. The
current standard of care for GBM patients involves surgical resection followed by
radiation and chemotherapy with an oral alkylating agent Temodar [14]. Most
patients with GBM survive less than a year after diagnosis. This extreme mor-
tality rate, where none have a long-term survival, has drawn significant attention
to improving treatment for these tumors. GBMs are not cured by surgery due
to the complex nature of the tumor and variable location of the tumor cells in
the brain, resulting in the inability to completely resect this tumor [8]. Chronic
diseases are the worlds leading cause of death. Diabetes is a complex disease,
often found to co-occur with other chronic conditions such as hypertension and
depression, which not only complicates diabetes management and but also in-
creases the risk of developing diabetes by 60% [3]. Majority of patients with
diabetes in the U.S. do not achieve the recommended guidelines. [18]. Dispari-
ties in treatment are present as well: significantly fewer Black and Latino adults,
low-and middle-income adults, and uninsured adults received recommended dia-
betes care compared with white, high-income, and insured adults between 2002
and 2007 [2].
With the enforcement of electronic medical records(EMRs), a vast amount
of healthcare data is being captured. Using various techniques in data mining
we can improve decision-making. The results of healthcare data analysis can
influence cost, revenue and quality of care [10]. Decision trees have been used
extensively based on extensive medical data and clinical evidence to develop
decision support systems and stored in a relational database [21]. For this dis-
sertation, we aim at using techniques of information processing and data mining
to make use of historical data about patients, guidelines of treatments given to
them, health outcomes, complications, etc to develop a set of algorithms and
implement them in a decision support tool.
2 Problem Definition and Goals of Research
We propose to develop a framework to evaluate efficiency of treatments in terms
of outcomes using clinical patient data. Outcomes of interest include likelihood
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of survival, longevity, probability of hospital admissions within one year, proba-
bility of hospital readmission within 30 days, etc. Short and long term economic
outcomes are equally important. We identify characteristic treatment patterns
and associate these patterns with patients having similar outcomes.
So far we have been working with GBM which is a rare disease. Our scope
covers chronic diseases like Diabetes Mellitus to investigate the validity and ac-
curacy of prediction in both cases. After preliminary discussions with domain
experts regarding different cancers and diabetes we anticipate that our general
approach will be equally applicable in multiple acute and chronic clinical sit-
uations where preliminary and secondary treatments are well understood, but
subsequent treatment may have too many options. A systematic decision sup-
port methodology would be best suited for both chronic and rare diseases. We
identify clinical and behavioral similarities among patients and create patient
cohorts based on the similarities found. A clinically relevant distance measure
needs to be developed to perform patient profiling [24]. This ‘patient similarity
assessment needs extensive exploration for studying the treatments prescribed
to different cohorts and help in treatment comparison, management of patients
in groups and prediction. Heuristics would be developed to rank the identified
treatment patterns for an individual patient based on the extent of similarity a
new patient shares with classes of patients. The model would also be enhanced
to incorporate various responses to treatments.
The goals of my research are as follows:-
1. Understanding the disease: A comprehensive understanding of how the
disease affects people, the preferred first and second line of treatments, vari-
ations in standard of care, treatment options other than the standard of
care, and the circumstances under which a particular course of treatment is
prescribed.
2. Creating a decision support tool: Models would be built to assist med-
ical professionals in deciding the most probable treatment patterns for in-
dividual patients by learning from historical data. There are three subgoals
here: a) Recognition of treatment patterns characteristic of a particular out-
come or multiple outcomes; b) Defining a similarity measure for patients
based on their clinical characteristics; and c) Developing a ranking algorithm
to order the treatment patterns to achieve the best outcomes for individual
patients or patient cohorts based on their similarity to classes of patients.
3. Evaluation of the decision support tool Evaluation of the models would
be done by training and testing our algorithms on datasets provided by our
partner institutions in this study. The treatments prescribed by the doctors
would be compared with the one recommended and ranked by our tool.
Validation of our approach would be done using various measures such as
receiver operating characteristic curve, accuracy, precision, and recall.
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3 Methods and Techniques
3.1 Data Representation
A prototype model is being developed for GBM patients using clinical and ge-
nomic data from a public portal called ‘The Cancer Genome Atlas Portal’ [12]
and cBioPortal [4]. The clinical domain includes demographic information about
the patient along with some basic clinical features, e.g Karnofsky performance
score,histological type, survival duration, prior glioma information and most im-
portantly the vital status of the patient (Living / Dead). Studies show that
GBM patients can be classified into four subtypes namely Classical, Mesenchy-
mal, Proneural and Neural based on the expression levels of a particular set of
genes [7, 23]. For our study we considered these set of genes and used their mRNA
expression levels, copy number varation data and methylation status. Additional
information includes drugs prescribed along with their dosage, therapy type, ra-
diation type, radiation dosage, and start and end dates for the treatment. We
model this data as a graph where nodes are of two types: ‘patient node’ & ‘treat-
ment type node’ and edges are also of two types: ‘prescription edge’ & ‘sequence
edge’. A graph offers a much richer picture of a network, and relationships of
several types. Since the data model has a path-oriented nature, the majority of
path-based graph database operations are highly aligned with the way in which
the data is laid out hence increasing the efficiency [16]. Figure 1 shows the current
representation of the data as a graph. The figure shows a graph consisting of two
patients just for illustrative purposes. In the graph patient nodes have properties
such as ‘patient id’, ‘age’, etc. Drugs and radiation prescribed are represented as
treatment type nodes with properties such as ‘drug name’ and ‘radiation type’
respectively. The ‘prescription edge’ signifies the prescription of treatment with
properties such as ‘start date of prescription’, ‘end date of prescription’, ‘dosage’,
etc. The ‘sequence edge’ signifies the sequence in which drugs or radiation were
prescribed. E.g., The edge labeled ‘Prescribed’ between the patient node with ‘id
= Patient 1’ and the drug node with ‘drugName = Drug A’ signifies that ‘Pa-
tient 1’ was prescribed 200 mg/day of ‘Drug A’ on 05/21/2007 till 06/22/2007.
The other type of edge labeled ‘Followed by’ would always be between two drugs
or two types of radiation or between a radiation type and a drug signifying the
sequence of the prescription. E.g., the ‘Followed by’ edge between source node
‘Drug A’ and target node ‘Drug B’ with properties ‘patient’ and ‘overlap’ sig-
nifies that for ‘Patient 1’, Drug A was followed by Drug B and there was an
overlap of 24 days. The graph shown in the above figure is based on the data
available for GBM patients. The structure of the graph would be enhanced for
the Diabetes patients since the chronicity of the disease and its commonly co-
morbid state with other conditions such as hypertension and clinical depression
yields many more parameters and potential complications to consider.
3.2 Approach
Our approach is driven by the outcome of the treatment. If survival is the out-
come, the objective is to increase the survival period of the patient as much
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Fig. 1. Data represented as a graph
as possible. For GBM patients we analyze the treatment data of patients and
identify treatment patterns, which are characteristic of survival for a certain
range of time (e.g., 6-12 months). The notion of ‘patient similarity’ would be
explored to either use existing similarity measures or develop a new metric for
the purpose of identifying similar patients which would play a significant role
in recommending treatment for a cohort of patients. Significant work has been
done at the Healthcare Systems and Analytics Research department of IBM in
the area of patient similarity involving physician feedback as an important pa-
rameter to group similar patients [22]. Chan et al (2010) [5] have proposed a new
patient similarity algorithm named SimSVM, which does a binary classification
and outputs the predicted class which is survival greater than 12 months or less
than 12 months and degree of similarity or dissimilarity. Their approach only
considers a single outcome and a few similarity measures as input. We believe
that our approach will be a significant enhancement since we plan to consider
multiple outcomes together as we believe that a single outcome based approach
could be misleading. For each individual patient we would rank the treatment
patterns based on historical experience with similar patients. Heuristics would
be developed to do the ranking.
We categorize the patients based on some outcome variable as a range of val-
ues: e.g., survival period of ‘less than 6 months’, ‘6-12 months’, ‘12-18 months’,
etc. The treatments for all the patients in each period would be represented
as a graph. Sequential pattern mining techniques such as GSP (Generalized
Sequential Patter mining) [1] & SPADE (Sequential Pattern Discovery using
Equivalence classes) [25] have been applied to come up with a “predominant”
treatment pattern for every period. This pattern may consist of a combination
of multiple drugs following a sequence and would be characteristic of a partic-
ular survival period representing the most commonly used treatment associated
with that period. These techniques are motivated by association rule mining
techniques such as the Apriori algorithm. Initially a combination of N=2 drugs
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following a sequence are accounted for and the ones prescribed to a significant
number of patients are considered for further analysis wehre‘N’ is the number of
drugs. This is followed by a combination of N+1 drugs and so on and so forth.
The algorithm terminates when no more significant combinations can be formed.
These patterns are used as features to classify patients based on survival periods.
The goal is to find patterns best suited for a particular profile of patients
sharing similar clinical and/or genomic characteristics. For a recently diagnosed
patient we would filter out patient profiles which share similarity above a par-
ticular threshold. Even though all the candidate patient profiles have clinical
similarity with the test patient, their degree of similarity may vary and would be
reflected through the distance metric that we proppose to use. Due to the differ-
ence in the extent of patient similarity, we would assign weights to the treatment
patterns prescribed to patients belonging to a particular profile. These weights
would be dependent on the following parameters:
1. Distance between the test patient and the candidate patient class: The weight
assigned to treatment patterns characteristic of a particular patient class is
inversely proportional to the distance from the test patient than another
candidate class.
2. Number of candidate patients following a particular type of treatment pat-
tern with respect to a particular profile: The larger the number of patients
following a particular treatment pattern, the higher the weight. A particular
treatment pattern may have different weights for different patient profiles.
3. Other criteria could include the degree of side effects, the extent of adverse
reactions in patients and several other clinical considerations as determined
by some consensus among physicians
4 Preliminary Results
Preliminary analysis on the GBM data was performed and a classification model
to predict the survival period of patients was developed. Our goal in this anal-
ysis was to perform a binary classification of the patients into 2 classes based
on survival period; namely, a) patients surviving more than 1 year b) patients
surviving less than 1 year and report the features, which are predictive of the
survival duration. A linear classifier (Logistic Regression) was trained based on
the clincal and the genomic features recorded before the treatment was started
and the sequential patterns which were were extracted based on the treatment
administered to the patients within one year of their diagnosis. For this exper-
iment we did not consider the drugs prescribed as standard of treatment to
train the classifier. Forward feature selection was used to pick predictive fea-
tures for the model. The Area under the receiver operating characteristic curve
(AUC) [19] and accuracy used for evaluation of the model are reported in Table
1. The predictive features influencing the survival period of GBM patients are
shown in Table 2.
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Table 1. Table 1. Performance of various feature combinations in predicting the sur-
vival period of GBM patients
Model AUC Accuracy
Clinical Features 0.66 +/- 0.166 68% +/- 9.33%
Treatment Patterns 0.69+/-0.059 70% +/- 8.08%
Genomic Features 0.70+/-0.10 70% +/- 10.49%
Genomic Features and Treatment Patterns 0.76 +/- 0.078 75.7% +/- 5.72%
Treatment Patterns and Clinical Features 0.77 +/- 0.078 74.7% +/- 6.27%
Genomic Features and Clinical Features 0.78 +/- 0.048 76.38% +/- 4.56%
Genomic Features and Treatment Patterns and Clinical Features 0.80 +/- 0.07 78.6% +/- 8.27%
Table 2. Table 1. Predictive Features influencing the survival period of GBM patients
to be greater than one year
Predictive Features
Genomic
EFGR copy number variation = -1 (hemizygous deletion)
GABRA1 mRNA expression z-score between 1 and -1
OLIG2 mRNA expression z-score between -2 and -2.5
PDFGRA mRNA expression z-score between -1.5 and -2
RELB mRNA expression z-score between -1.5 and -2
SYT1 mRNA expression z-score between 1 and 1.5
TP53 mRNA expression z-score between -1.5 and -2.5
Clinical
Age of patient at pathologic diagnosis
Karnofsky performance score
Treatment Patterns
External Beam Radiation therapy followed by prescription of Temodar followed by Avastin
Prescription of Dexamethasone
Prescription of Temodar followed by CCNU
Prescription of Temodar followed by External Radiation followed by Dexamethasone
5 Related Work
Some work has been done in the area of developing models for predicting treat-
ment plans for patients. Research groups have developed models to predict the
various drug interventions as well as drugs coupled with lab interventions that
would work best for a particular disease. These models do not include some
important parameters like symptoms, results of investigations, laboratory test
results, etc. The treatment plan predicted by these models is only limited to
drugs that may be effective [15]. We consider a very comprehensive definition of
a treatment plan and the approach outlined previously would predict, besides
important drugs, the dosage of each drug, duration of drug therapy, types of
interventions, duration of a particular intervention, etc. tailored to a particular
patient profile. Based on the models built by Kim. et al (2004) [9] for chronic
heart failure (CHF) treatment, significant factors improving the plasma BNP
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levels were discovered . which were validated by large-scale trials. Similar work
has been done in the area of heart disease diagnosis reporting fairly good accu-
racy [20]. Neuvirth et al (2011) [13] present a prototype for a data-driven risk
assessment system for Diabetes patients and claim to identify physicians who can
deliver optimal care to such patients and also identify patients requiring emer-
gency care services. The first model predicting high risk patients was a binary
classification to predict whether a patient attended ‘Urgent Care’ services in a
specific period of time. The AUC (Area under the curve) used to validate the
classification ranged from 0.57 0.71 which does not seem to be a very significant
classification. The second model predicting best physician match, uses features
that categorizes the match of the patient and the physician by quantifying the
similarity of the patient to the characteristic population of the physician. The
AUC for this model is approximately 0.59 and based on this result the authors
claim that personalized physician assignment plays a role in the treatments suc-
cess. The decision support model developed by Chen et al(2012) for Diabetes [6]
uses a case based reasoning approach to find patient cases similar to the one
queried and is not very robust since the approach used by authors to find simi-
lar cases is not very granular and eventually the same line of treatment which is
given to these similar cases is recommended for the new patient. In our approach
we will take into consideration all the cohorts of patients similar to the test pa-
tient and then assign weights to the treatment pattern in each cohort, which
we believe would be more accurate than the case based reasoning approach.
We extensively tease out the different treatment patterns that are characteristic
of a particular outcome and plan to come up with a meaningful measure of pa-
tient similarity to build patient profiles based on clinical and possibly behavioral
variables, especially for diabetes. We believe our approach to assign weights to
different treatment patterns for a particular patient profile is also very com-
prehensive and unique especially because we will be relying on consensus from
domain experts for individual diseases.
6 Expected Outcomes
Most of the work mentioned below will feed into the prototype development
work. Actual testing will be done for the validation of algorithms with available
data. Overall testing of our treatment suggestion system will be done in con-
junction with the prototype implementation.
Models: A graph structure is being used to capture GBM data but keeping
in mind the extensive nature of chronic disease data, some changes might have
to be made to the existing graph structure. We are currently exploring various
sequential pattern mining techniques and evaluating them given the complex
nature of the graphs we have [11]. These models are subjected to a variety of
analyses. Our overall approach can be considered as a predictive model for cap-
turing historical patient treatment data and coming out with a ranked scheme
for possible treatments that would be targeted to certain desired outcomes.
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Algorithms: A variety of algorithms will be designed including sequential pat-
tern mining algorithms to analyze treatment data with mutiple parameters, clus-
tering algorithms to cluster patients into patient cohorts , algorithms to define a
patient clinically in terms of patient similarity or to define the distance of a pa-
tient from a patient class. In addition to these, weighting and ranking algorithms
for treatments would also be designed.
7 Contribution of Dissertation
The dissertation is focussed on developing a decision support model for rare and
chronic diseases and finding treatment patterns which can influence a particular
outcome or multiple outcomes. In the paper we presented the first step in min-
ing significant sequential treatment patterns and correlating the patterns with
survival period of patients. From a clinical perspective, it gives an insight to
the medical community about the significance of prescribing a set of drugs in
a particular sequence. Our current approach unlike previous approaches takes
into account duration of prescription of drugs, overalpping prescriptions, etc. We
would also incorporate decision making based response shown by patients to the
treatments recommended under different circumstances. We are currently ex-
ploring the area of patient similarity to form cohorts of patients sharing similar
clincal features. Each cohort of patients may have different treatment patterns
which are more predominant than the other which would help us in assigning
weights to the treatment patterns in addition to inputs from domain experts.
Based on the level of similarity shared by a newly diagnosed patient we would
recommend treatment guidelines. Using a variety of available clinical features
about patients and their treatments we plan to develop a comprehensive testbed
of decision models.
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